Empiget tabs 10mg 14s

Empagliflozin 10mg

EmpIget tablets contain empagliflozin, an orally active inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for the reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose and thereby increases urinary glucose excretion. Empiget is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus as follows: Monotherapy: When diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy: In combination with other glucose–lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycemic control.